The secondary end point of MPR rate in patients with a PD-L1 tumor proportion score (TPS) of <1%, 1–49% and ≥50% at screening was 11% (6 of 53), 5% (1 of 20) and 33% (15 of 45), respectively (P = 0.01, two-sided Fisher’s exact test). This evidence concerns the gene CD274 and neoplasm.